21:17 , Dec 14, 2018 |  BC Week In Review  |  Company News

LG Chem and Avacta partner to develop undisclosed targets

Avacta Group plc (AIM:AVCT) granted LG Chem Ltd. (KRX:051910) exclusive, global rights to develop Affimer candidates against multiple undisclosed targets to treat inflammatory disorders and cancer. Avacta may receive up to $180 million in up...
20:46 , Jan 26, 2018 |  BC Week In Review  |  Company News

Avacta, OncoSec combine technologies

Avacta Group plc (LSE:AVCT) and OncoSec Medical Inc. (NASDAQ:ONCS) partnered to combine Avacta’s Affimer protein platform, including its PD-L1 inhibitor AVA04, with OncoSec’s gene delivery technology ImmunoPulse. Avacta said the companies will work together to...
19:41 , Nov 8, 2016 |  BC Week In Review  |  Company News

Avacta, Memorial Sloan Kettering deal

Avacta and Memorial Sloan partnered to evaluate Avacta’s Affimer technology in CAR T cell applications. Affimers are non-antibody scaffold proteins, which the company said may have advantages over antibody fragment technology. Avacta will develop Affimers...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Avacta, Glythera deal

Avacta and Glythera partnered to develop targeted therapeutics using Avacta’s Affimer technology and Glythera’s PermaLink conjugation chemistry. The partners said Affimer reagents and PermaLink chemical linkers offer more stable attachment of toxins and provide more...
07:00 , Jul 21, 2016 |  BC Innovations  |  Emerging Company Profile

Drugging the undruggable

One of the main limitations of the many knockout and knockdown screens used in identifying new drug targets is that they don't allow protein expression and therefore reveal no information about how to drug the...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

Avacta, Mologic deal

Avacta and Mologic partnered in a non-exclusive deal to develop rapid lateral flow diagnostics for clinical applications using Avacta’s Affimer technology. The companies will share revenues from resulting marketed diagnostics. Avacta did not disclose financials....
07:00 , Jul 20, 2015 |  BC Week In Review  |  Financial News

Avacta proposes placing

Avacta Group plc (LSE:AVCT), Heslington, U.K.   Business: Supply/Service   Date announced: 2015-07-15   Type: Placing   To be raised: Up to L22 million ($34.1 million)   Shares: 1.8 billion   Price: 1.25p   Placement...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Financial News

Avacta completes warrant exercise

Avacta Group plc (LSE:AVCT), Heslington, U.K.   Business: Supply/Service   Date completed: 3/22/11   Type: Warrant exercise   Raised: £72,500 ($117,726)   Shares: 29 million   Price: 0.25p   Shares after offering: 1.7 billion  ...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

Avacta, Pall sales and marketing update

Avacta and Pall will co-promote Avacta's Optim 1000 ultra-low volume biopharmaceutical analysis tool in North America. Optim 1000 was developed to accelerate the speed of drug development through early analysis of compounds to identify the...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Financial News

Avacta completes placing

Avacta Group plc (LSE:AVCT), Heslington, U.K.   Business: Supply/Service   Date completed: 1/21/11   Type: Placing   Raised: £2 million ($3.1 million)   Shares: 186.1 million   Price: 1.05p   Shares after offering: 1.6 billion...